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Decentralised HIV care during the COVID-19 
pandemic: Ensuring safe community-based 
services
To the Editor: Since the start of the COVID-19 pandemic, there have 
been significant concerns about disruptions to the continuum of HIV 
care worldwide.[1-6] Expansion of differentiated service delivery has 
been proposed as one strategy to maintain safe access to HIV care,[7] 
with increased use of differentiated services reported during the early 
stages of the COVID-19 pandemic.[8] Decentralised HIV care delivery 
programmes providing out-of-facility care, in particular, decrease 
frequency of visits to healthcare facilities,[7] minimising exposures to 
COVID-19 and allowing continuity of HIV care during lockdowns 
and other restrictions. However, providing decentralised, out-of-
facility HIV care during the pandemic requires access to COVID-19 
information, capacity to screen patients for COVID-19 symptoms and 
adequate supply of personal protective equipment at all points of care. 
Supporting staff and ensuring access to these resources may be more 
difficult in community-based sites.
We sought to evaluate perceptions of personal and facility 
preparedness among healthcare workers at primary health clinics 
and community-based pick-up points participating in a decentralised 
antiretroviral therapy (ART) delivery programme in KwaZulu-
Natal, South Africa. The Central Chronic Medicines Dispensing and 
Distribution programme allows stable, virologically suppressed patients 
to collect ART at community-based pick-up points, such as private 
pharmacies and churches.[9] We administered a telephone questionnaire 
to a convenience sample of staff in primary health clinics during April 
and May 2020 and staff in clinics and community-based pick-up points 
in August 2020 to assess access to COVID-19 information, available 
resources and perceived personal and facility preparedness. 
We completed interviews with 112 clinic staff (n=49 in April - 
May 2020; n=63 in August 2020) and 24 pick-up-point staff. Most 
clinic staff were healthcare providers (e.g. nurses, medical officers) or 
ancillary providers (e.g. counsellors), while pick-up-point staff were 
mainly pharmacists and dispensing clerks. Respondents primarily 
perceived an increased need for prevention procedures and supplies 
(59%) as a challenge to their work during April - May, and COVID-
19 infection risk (48%) in August. By August 2020, nearly all clinic 
staff reported access to resources (94%) and space (100%) to screen 
patients for COVID-19, while significantly fewer pick-up-point 
staff reported access to these tools (54%; p<0.001). In August 2020, 
pick-up-point staff, compared with clinic staff, reported significantly 
lower rates of access to information to perform work duties during 
the COVID-19 pandemic (67% v. 94%; p=0.003), perceived facility 
preparedness to work with COVID-19 patients (54% v. 81%; p=0.016) 
and access to the necessary protective equipment (50% v. 89%; p<0.001). 
Our results suggest that staff working in out-of-facility, community-
based sites participating in decentralised HIV care programmes do 
not feel as prepared to work with patients during the COVID-19 
pandemic, or do not have access to the necessary supplies to carry out 
this work safely, compared with their clinic-based counterparts. While 
further study is needed, our results highlight that if differentiated 
service delivery is to fulfil its potential to ensure continuity of care 
for people living with HIV during the COVID-19 pandemic, staff at 
all programme levels and sites must be appropriately supported and 
prepared to deliver care safely to their patients. 
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